Premium
Effect of single dose administration activated charcoal containing sorbitol on serum sodium concentration and hydration status in dogs
Author(s) -
Mix Katherine A.,
Stafford Jennifer,
Hofmeister Erik
Publication year - 2019
Publication title -
journal of veterinary emergency and critical care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.886
H-Index - 47
eISSN - 1476-4431
pISSN - 1479-3261
DOI - 10.1111/vec.12887
Subject(s) - medicine , activated charcoal , hematocrit , blood urea nitrogen , hypernatremia , creatinine , anesthesia , sodium , zoology , chemistry , organic chemistry , adsorption , biology
Objective To assess the administration of a commercially available activated charcoal suspension with sorbitol (ACS) on serum sodium concentrations and hydration status in healthy dogs. Design Prospective study. Setting Private referral hospital. Animals Nine healthy adult dogs. Interventions Dogs were administered 1 mg/kg maropitant (Cerenia; Pfizer Animal Health, New York, NY) intravenously 1 hour prior to charcoal administration. Dogs were administered a single dose of 2 g/kg ACS. Measurements and Main Results Blood samples and body weights were obtained prior to charcoal administration and 2, 4, 6, 8, 10, and 12 hours post ACS administration. Venous sodium, potassium, chloride, blood urea nitrogen, creatinine, lactate, packed cell volume, and total plasma protein were measured at each time interval. All dogs returned 2–4 weeks after ACS administration for a 12 hour period of water restriction and to serve as their own control group. The same measurements were repeated during water restriction period as following ACS administration. The increase in serum sodium concentration was significantly higher following ACS administration when compared to control period ( P = 0.0002). All dogs administered ACS experienced a significant degree of weight loss ( P = 0.0371) when compared to the control period. Following administration of ACS, the hematocrit of the dogs administered ACS was found to be significantly increased ( P = 0.0001), when compared to the control period. Conclusion Patients that are administered a single dose of ACS are at risk of developing dehydration and secondary hypernatremia as observed in the dogs during the study period. Patients receiving ACS should have electrolytes monitored and would benefit from fluid therapy as previously recommended.